Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Chris Painter

Chris Painter

Research groups

Chris Painter

Health Economist

Chris Painter’s research focuses on using health economics and health technology assessment methods to inform resource allocation policy decisions for a wide range of communicable and non-communicable diseases. This typically involves a comparison between the economic costs and health impacts of different health interventions to understand which intervention(s) are most cost-effective to use in practice.

A Health Economist at MORU MAEMOD’s Neglected Tropical Diseases Modeling (NTDM) Group since 2022, Chris’ current work focusses on: (ACORN) A Clinically Oriented antimicrobial Resistance Network; the ACT-South Asia (Azithromycin and Cefixime treatment of typhoid in South Asia) trial; and working with LOMWRU, MORU’s Lao PDR Unit, on the newly formed Unit for Health Evidence and Policy (UHEP) in Vientiane.

Chris’ ongoing research interests include antimicrobial resistance (AMR); COVID-19; Hepatitis C virus; and health economics and health technology assessment methods and institutionalising these methods in low- and middle-income countries (LMICs)

Holder of both an MSc and a BSc Economics from the University of Manchester, prior to MORU Chris worked as a health economist in the UK private sector and as an Overseas Development Institute Fellow (2019-2022) at the Health Intervention and Technology Assessment Program (HITAP) in Thailand’s Ministry of Public Health.